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AbstractThis study characterized EMRSA-15 isolates obtained from patients in Kuwait hospitals for their genotypic relatedness, antibiotic resistance
and carriage of virulence genes using pulsed-ﬁeld gel electrophoresis (PFGE), coagulase serotyping, SCCmec subtyping, spa typing, multilocus
sequence typing and DNA microarray. The isolates were resistant to trimethoprim (75.6%), ciproﬂoxacin (29.7%), erythromycin and
clindamycin (24.3%), tetracycline (19.0%), and gentamicin and kanamycin (21.6%). All 37 isolates belonged to sequence type (ST) 22,
coagulase type XI, three PFGE types and eight subtypes, ten spa types including t223 (51.3%), t852 (13.5%), t032 (8.1%), t790 (8.1%),
t3107 (5.4%) and one each of t309, t2251, t3935, t5708 and t5983. Twenty-six isolates (70.2%) carried SCCmec IVa, eight isolates
carried SCCmec IV and three isolates carried SCCmec IVh. All isolates carried agr1, cap5 and egc gene cluster (seg, sei, selm, seln, selo,
and selu). tst (toxic shock syndrome toxin) was detected in 23 isolates. Eight isolates (21.6%) were positive for Panton-Valentine
leukocidin (PVL). Genotypic analysis revealed that 62.1% of the isolates comprising ST22-IVa-t223 (51.3%) and ST22-IVa-t309/t2251/
t3935/t5708 (10.8%) were CC22-[tst1+] UK EMRSA-15/Middle Eastern variant, 21.6% were CC22-PVL+ EMRSA-15 variant and 16.2%
were CC22-UK EMRSA-15/Barnim clone. These results show that the tst1 positive-ST22-IVa-t223 (Middle Eastern variant) and the
CC22-PVL+ EMRSA-15 variant were the dominant EMRSA-15 variants in Kuwait hospitals.
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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E-mail: EDET@hsc.edu.kwIntroductionMethicillin-resistant Staphylococcus aureus (MRSA) strains
continue to be isolated from both healthcare- and community-
associated infections in different parts of the world. The in-
crease in the number of MRSA infections reported worldwide
has been accompanied by changes in the characteristics of
MRSA strains emerging in different parts of the world [1].
Consequently, epidemiologic typing using a combination of
phenotypic and genotypic typing methods has contributed to
our understanding of changes in the clonal distribution of MRSAw Microbe and New Infect 2016; 12: 24–30
2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
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p://dx.doi.org/10.1016/j.nmni.2016.03.008isolated in different geographical locations over time. Whereas
MRSA isolates obtained in the 1960s (early or classic MRSA)
were usually susceptible to majority of non-β-lactam antibiotics,
those isolated in the late 1970s and beyond were multiply
resistant to non-β-lactam antibiotics and were described as
epidemic MRSA (EMRSA) because of their capacity to spread
extensively and cause serious infections among hospitalized
patients [1,2]. Epidemiologic typing by Kerr et al. [3] and
Aucken et al. [4] identiﬁed 17 different EMRSA clones, desig-
nated EMRSA-1 to EMRSA-17, in the United Kingdom.
The EMRSA-15 clone was ﬁrst characterized in England on the
basis of phage typing (a weak lysis pattern with phage 75), sus-
ceptibility to antimicrobial agents and failure to produce urease
[5]. The urease-negative phenotype resulted from a single
nucleotide deletion within the UreC gene, leading to a frameshift
inactivation of the alpha subunit of the urease gene [6]. Subse-
quently, multilocus sequence typing of the EMRSA-15 strains
classiﬁed them as multilocus sequence (ST) type 22 (ST22) [7].iology and Infectious Diseases
.0/)
NMNI Udo et al. EMRSA-15 in Kuwait hospitals 25EMRSA-15 strains are an important cause of nosocomial
bacteraemia in many UK and Irish hospitals [8], and they are a
major pathogen in other European healthcare facilities [9,10].
EMRSA-15 strains have also been isolated in Australia [11],
Singapore [12], India [13,14], Malaysia [15], Kuwait [16], Saudi
Arabia [17], United Arab Emirates [18], Qatar [19] and Oman
[20]. The survival and widespread transmission of EMRSA-15
strains have been attributed to genetic changes within the
bacterial genome due to the acquisition of antibiotic resistance
and virulence genes and adaptation to the healthcare environ-
ment [6].
Molecular characterization of EMRSA-15 strains isolated in
the Gulf Cooperative Council (GCC) countries have revealed
different genetic backgrounds with different antibiotic suscep-
tibility patterns. Whereas EMRSA-15 isolates from the United
Arab Emirates belonged to spa types t032 or t005 [18], the
majority of recent isolates from Qatar [19] and Oman [20]
belong to t852.
In this study, we investigated EMRSA-15 isolates obtained in
Kuwait public hospitals using a combination of molecular typing
methods to establish their genetic relatedness to EMRSA-15
isolated in the United Kingdom and other GCC countries.Materials and MethodsMRSA isolates
A total of 37 EMRSA-15 strains, isolated in the years 2005 (four
isolates representing four pulsed-ﬁeld gel electrophoresis
(PFGE) patterns) and 2010 (33 isolates), were included in this
study. These MRSA isolates were among clinical isolates sub-
mitted to the MRSA Reference Laboratory, Kuwait, for mo-
lecular typing. The MRSA isolates were obtained as part of
routine bacteriology services in the individual hospital labora-
tories and were archived at the MRSA Reference Laboratory,
Kuwait. The MRSA isolates were isolated at ten hospitals:
Mubarak (nine isolates), Al Sabah (seven isolates), Ibn Sina (ﬁve
isolates), maternity hospital (ﬁve isolates), Adan (three iso-
lates), Al Razi (three isolates), Farwaniya (two isolates), Jahra
(one isolates), Armed Forces (one isolate) and Chest Disease
Hospital (one isolates). Isolates were identiﬁed by cultural
characteristics, Gram staining, and positive tube coagulase and
DNase tests. The isolates were preserved in glycerol 40% (v/v)
in brain heart infusion broth (Oxoid, Basingstoke, UK) at −80°
C. They were recovered by subculturing in brain–heart infu-
sion broth at 37°C for 24 hours followed by two further
subcultures on brain–heart infusion agar. Preliminary identiﬁ-
cation of MRSA isolates as EMRSA-15 was based on negative
urease test [5] and carriage of SCCmec type IV genetic
element.© 2016 The Authors. Published by Elsevier Ltd on behal
This is an oUrease production
Urease production was detected on Christensen urea agar slope
after 72 hours’ incubation at 35°C as described previously [5,16].
Antibacterial susceptibility testing
Antibacterial susceptibility testing was performed by the disk
diffusion method [21] with the following antimicrobial disks
(Oxoid): benzyl penicillin (10 U), cefoxitin (30 μg), kanamycin
(30 μg), mupirocin (200 and 5 μg), gentamicin (10 μg), eryth-
romycin (15 μg), clindamycin (2 μg), chloramphenicol (30 μg),
tetracycline (10 μg), trimethoprim (2.5 μg), fusidic acid (10 μg),
rifampicin (5 μg), ciproﬂoxacin (5 μg), teicoplanin (30 μg) and
linezolid (30 μg). Minimum inhibitory concentration for cefox-
itin, vancomycin and teicoplanin were determined with Etest
strips (bioMérieux, Marcy l’Étoile, France) according to the
manufacturer’s instructions. S. aureus strain ATCC 25923 was
used as a quality control strain for susceptibility testing. The
Dtest was used to test for inducible resistance to clindamycin.
Molecular typing of isolates
Isolates were typed by PFGE, coagulase gene typing, SCCmec
typing, spa typing and multilocus sequence typing (MLST). PFGE
was performed on all 37 MRSA isolates as described previously
[22]. DNA for PCR ampliﬁcation was isolated and puriﬁed as
described previously [20]. Coagulase typing was performed as
described previously [23]. For the detection of coagulase type XI,
primer pair (coaS-F) 50-TGGGCAATTACATTTTG GAG-30 and
(coaS-XI-R) 50-TCGTTTGGGTAAGTTGCTTT-30 (395 bp)were
designed and used in this study. PCR ampliﬁcation was carried out
on a Gene AMP PCR System 9700 instrument (Thermo Fisher
Scientiﬁc Life Sciences,Waltham,MA,USA) in a total volumeof 25
μL of reaction mixture containing 12.5 μL of AmpliTaq Gold
master mix (Roche, Basel, Switzerland), 50 pmol of each primer
and 2 μL of extracted DNA. The PCR reaction was 95°C for 15
minutes, followed by 30 cycleswith 95°C for 30 seconds, 56°C for
40 seconds, 72°C for 30 seconds and a ﬁnal extension stepof 72°C
for 5 minutes. PCR products were analysed by agarose gel elec-
trophoresis using 2% (w/v) agarose in Tris-EDTA buffer.
SCCmec typing was performed by PCR assays as described
previously [24,25]. spa typing was performed as described by
Harmsen et al. [26]. Clonal relatedness of the spa types was
determined by the BURP (Based Upon Repeat Pattern) algo-
rithm as described by Mellmann et al. [27]. MLST was per-
formed on all 37 isolates as described by Enright et al. [7].Detection of genes for antibiotic resistance and
virulence
DNA microarray analysis using Identibac S. aureus Genotyping
Kit 2 (Alere Technology, Jena, Germany) was used following
protocols provided by the manufacturer. Data generated weref of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 12, 24–30
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
TABLE 1. Source and characteristics of MRSA isolates in Kuwait hospitals
Strain No. Year Hospital Gender Source PFGE SCCmec type spa type
Kuwait_70 2005 Armed Forces M Sputum B1 IVh t032
Kuwait_64 2005 Mubarak M Swab A5 IVa t223
Kuwait_74 2005 Mubarak M Wound A3 IVa t223
Kuwait_51 2005 Mubarak M Nasal C IVa t2251
Kuwait_270 2010 Farwaniya M Nasal B IVh t032
Kuwait_376 2010 CDH M Wound B1 IVh t032
Kuwait_359 2010 Sabah F Nasal A IVa t223
Kuwait_365 2010 Maternity F Nasal A1 IVa t223
Kuwait_366 2010 Al-Razi M Wound A1 IVa t223
Kuwait_368 2010 Mubarak M Nasal A IVa t223
Kuwait_369 2010 Sabah M Nasal A IVa t223
Kuwait_370 2010 Ibn-Sina M Nasal A IVa t223
Kuwait_371 2010 Al-Razi F Nasal A IVa t223
Kuwait_372 2010 Jahra F Ear A IVa t223
Kuwait_378 2010 Mubarak M Nasal A IVa t223
Kuwait_380 2010 Maternity — Nasal A4 IVa t223
Kuwait_384 2010 Ibn-Sina M Nasal A2 IVa t223
Kuwait_385 2010 Ibn-Sina M Axilla A2 IVa t223
Kuwait_387 2010 Mubarak F Nasal A3 IVa t223
Kuwait_388 2010 Mubarak M Bed sore A IVa t223
Kuwait_391 2010 Sabah M Nasal A2 IVa t223
Kuwait_398 2010 Mubarak M Nasal A1 IVa t223
Kuwait_400 2010 Sabah F Ear A IVa t223
Kuwait_229 2010 Maternity F Nasal A IVa t309
Kuwait_361 2010 Ibn-Sina M Swab B IV t3107
Kuwait_363 2010 Sabah M Sputum B IV t3107
Kuwait_386 2010 Al-Razi M Ulcer A6 IVa t3935
Kuwait_377 2010 Sabah M Groin A IVa t5708
Kuwait_379 2010 Adan M Nasal B2 IV t5983
Kuwait_373 2010 Maternity F HVS B1 IVa t790
Kuwait_374 2010 Sabah M Nasal B1 IVa t790
Kuwait_375 2010 Ibn-Sina F Sputum B1 IVa t790
Kuwait_360 2010 Adan F Abscess B IV t852
Kuwait_362 2010 Farwaniya F Nasal B IV t852
Kuwait_364 2010 Mubarak M Groin B IV t852
Kuwait_367 2010 Adan F Pus B IV t852
Kuwait_399 2010 Maternity F Pus B IV t852
CDH, Chest Disease hospital; MRSA, methicillin-resistant Staphylococcus aureus; HVS, high vaginal swab; PFGE, pulsed-ﬁeld gel electrophoresis.
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Reader (Alere Technology), which assigned MRSA isolates to
STs and clonal complexes (CCs) by comparing each isolate to
STs and CCs of previously characterized isolates in the
ArrayMate database [28,29].
ResultsTheMRSA isolates were obtained from nasal swabs (n = 18), skin
and soft tissues (n = 10), sputum (n = 3), groin (n = 2), ear (n = 2),
and vaginal swab and axilla (n = 1 each). The patients consisted of
23 men and 13 women. The sex of one patient was not speciﬁed.
All 37 isolates were urease negative and were susceptible to
vancomycin and teicoplanin (minimum inhibitory concentration
1.5 mg/L), linezolid, chloramphenicol, rifampicin, mupirocin
and fusidic acid but resistant to trimethoprim (n = 28; 75.6%),
ciproﬂoxacin (n = 11; 29.7%), erythromycin and clindamycin
(n = 9; 24.3%), gentamicin and kanamycin (n = 8; 21.6%), and
tetracycline (n = 7; 19.0%).
Molecular typing of MRSA isolates
The isolates were grouped into three PFGE patterns, desig-
nated types A (22 isolates), B (14 isolates) and C (one isolate),
as summarized in Table 1 and Fig. 1.© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4All 37 isolates belonged to coagulase type XI, ST22, and
carried SCCmec IV genetic element. SCCmec subtyping distin-
guished the isolates into subtypes IVa (n = 26, 70.2%) and IVh
(n = 3, 8.1%). Eight isolates (21.6%) had no subtypes. The iso-
lates belonged to ten spa types with 19 isolates (51.3%) assigned
to spa type t223, followed by t852 (n = 5; 13.5%), t790 (n = 3;
8.1%), t032 (n = 3; 8.1%) and t3107 (n = 2; 5.4%). spa types
t5983, t309, t5708, t3935 and t2251 occurred in one isolate
each. BURP analysis deﬁned one spa CC (spa-CC) 223 with the
founder as t223 (Fig. 2).
A combination of the molecular typing results revealed that
the isolates were ST22-IVa-t223 (n = 19; 51.3%), ST22-IV-t852
(n = 5; 13.5%), ST22-IVa-t790 (n = 3; 8.1%), ST22-IVh-t032
(n = 3; 8.1%) and ST22-IV-t3107 (n = 2; 5.4%). ST22-IVa-t309,
ST22-IVa-t2251, ST22-IVa-t3935, ST22-IVa-t5708 and ST22-IV-
t5983 occurred in one isolate each (Table 2).DNA microarray analysis of isolates
DNA microarray analysis revealed that the 37 isolates were
positive for genes encoding accessory gene regulator type 1
(agrI), capsular polysaccharide type 5 (cap5), staphylococcal
enterotoxin egc gene cluster (seg, sei, selm, seln, selo and selu),
haemolysin beta (hlb), putative membrane protein (hl), staph-
ylokinase (saK) and chemotaxis inhibition protein (chp) butiology and Infectious Diseases, NMNI, 12, 24–30
.0/).
FIG. 1. Dendogram of pulsed-ﬁeld
gel electrophoresis patterns of ST22-
IV-MRSA isolates. MRSA, methicillin-
resistant Staphylococcus aureus.
NMNI Udo et al. EMRSA-15 in Kuwait hospitals 27differed in the carriage of sea, seb, sec, tst (toxic shock syn-
drome toxin), hlgA (haemolysin gamma A) and hla (haemolysin
alpha). Eight isolates (21.6%) consisting of t852, t3107 and
t5983 were positive for Panton-Valentine leukocidin (PVL)
(Table 2). None of the isolates was positive for sed.
As shown in Table 2, DNA microarray analysis classiﬁed the
isolates into three groups: CC22-UK EMRSA-15/Barnim-MRSA
clone, CC22-[tst1+] UK EMRSA-15/Middle Eastern variant and
CC22-PVL+ UK EMRSA-15. The CC22-UK EMRSA-15/Barnim-
MRSA clone comprised six isolates, which belonged to
SCCmec-IVh-t032 (three isolates) and SCCmec IVa-t790 (three
isolates), that were resistant to erythromycin and clindamycin
and carried ermC. The t790 isolates were positive for sec but
lacked hla and hlgA, which were present in t032 isolates.
The CC22-[tst1+] UK EMRSA-15/Middle Eastern variant
consisted of 23 isolates belonging to spa type t223 (n = 19) and
one isolate each of t309, t2251, t3935 and t5708. These isolatesFIG. 2. Population snapshot for MRSA BURP analysis. BURP grouping
using default parameters resulted in one spa CC. Each dot represents
unique spa type. Diameter of dot is proportional to quantity of cor-
responding spa type. Blue dots represent putative founder (i.e. spa type
with highest score within CC); yellow dots, subfounder with second
highest score. BURP, Based Upon Repeat Pattern); CC, clonal complex;
MRSA, methicillin-resistant Staphylococcus aureus.
© 2016 The Authors. Published by Elsevier Ltd on behal
This is an oharboured tst and were resistant to trimethoprim but differed
in their resistance to tetracycline, erythromycin and clindamy-
cin and carriage of virulence genes.
The CC22-PVL+ UK EMRSA-15 variant consisted of eight
isolates that belonged to spa types t852 (n = 5), t3107 (n = 2)
and t5983 (n = 1). These isolates were PVL positive and were
resistant to gentamicin, kanamycin, tobramycin, erythromycin,
clindamycin, trimethoprim and ciproﬂoxacin. The t852 isolates
were negative for scn, hla and hlgA.
DiscussionThe results of this study provide insight into the epidemiology of
EMRSA-15 isolates in Kuwait hospitals. Similar to EMRSA-15
isolates reported elsewhere [6,7,29], the isolates investigated in
this study belonged to ST22 and carried a type IV SCCmec genetic
element. However, molecular subtyping and DNA microarray
analysis revealed differences in their genetic backgrounds, sug-
gesting multiple origins for EMRSA-15 in Kuwait hospitals.
The study revealed that isolates ﬁtting the CC22-IV[tst1+] UK
EMRSA-15/Middle Eastern variant, consisting of spa types t223
(51.3%), t309 (2.7%), t2251 (2.7%), t3935 (2.7%) and t5708
(2.7%), constituted the dominant EMRSA-15 variant in Kuwait
hospitals in 2010. In addition, the t223 isolates widespread in the
country evidenced by their isolation in six of the ten hospitals
studied. The t223 isolates had antibiotic resistance and virulence
proﬁles similar to PVL-negative, tst-positive ST22-IV-t223 isolates
reported to have colonized children and parents in the Gaza
Strip [30,31] as well as PVL-negative, tst-positive ST22-IV-MRSA-
t223 recovered from healthy individuals in Jordan [32], making it
the dominant EMRSA-15 clade in the Middle East.f of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 12, 24–30
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).















2005 1 ST22-MRSA-IVh t032 E, CC, CIP ermC seb, sec sel, egc scn, hla, hlIII, hlgA
2010 2 ST22-MRSA-IVh t032 E (1), CC (1), CIP (2), W(1) ermC egc scn, hla, hlgA
2010 3 ST22-MRSA-IVa t790 E (2), CC (2) ermC sec, egc scn
UK EMRSA-15/Middle Eastern variant [tst+]
2005 2 ST22-MRSA-IVa t223 E (1), CC (1), TE (2), W (2) ermC, tetK, dfrS1 tst, egc scn, hla, hlgA
2010 17 ST22-MRSA-IVa t223 TE (4), W(16) tetK, dfrS1 tst, egc scn, hla, hlgA
2010 1 ST22-MRSA-IVa t309 W dfrS1 tst, egc scn, hla, hlgA
2005 1 ST22-MRSA-IVa t2251 TE tetK tst, egc scn, hla, hlgA
2010 1 ST22-MRSA-IVa t3935 W dfrS1 tst, sea egc scn, hla
2010 1 ST22-MRSA-IVa t5708 W tetK, dfrS1 tst, egc scn
CC22-MRSA-IV-PVL+
2010 5 ST22-MRSA-IV t852 CN (5), K (5), E (1), CC (1), TOB (4), W (3), CIP
(5)
aacA-aphD, aadD PVL, egc




PVL, egc scn, hla, hlgA
2010 1 ST22-MRSA-IV t5983 E, CC, W, CIP, CN, K, TOB ermC, aacA-aphD, aadD,
dfrS1
PV, egc scn, hla
All isolates carried hemolysin delta (hld) egc gene cluster (seg, sei, selm, seln, selo, selu).
CC, clindamycin; chp, chemotaxis-inhibiting protein; CIP, ciproﬂoxacin; CN, gentamicin; E, erythromycin; hl, putative membrane protein; hla, haemolysin alpha; hlb, haemolysin beta;
hlgA, haemolysin gamma, component A; hlIII, putative membrane protein; K, kanamycin; MRSA, methicillin-resistant Staphylococcus aureus; PVL, Panton Valentine leukocidin; sak,
staphylokinase; scn, staphylococcal complement inhibitor; TE, tetracycline; TOB, tobramycin; tst, toxic shock syndrome toxin; W, trimethoprim.
28 New Microbes and New Infections, Volume 12 Number C, July 2016 NMNIThe multiresistant CC22-MRSA-IV-PVL+ variant, consisting
of spa types t852 (13.5%), t3107 (5.4%) and t5983 (2.7%), was
the second most common EMRSA-15 variant in this study.
ST22-IV-MRSA-t852 isolates were reported among healthy
carriers and patients in Indian hospitals as early as 2008
[13,33], which may represent the origin of this EMRSA-15
variant. Since then, PVL-positive, multiresistant spa type t852
isolates have been reported among ST22-IV MRSA isolates in
Saudi Arabia [17], Qatar [19] and Oman [20], suggesting an
increasing transmission of this variant in the Gulf Cooperative
Council countries. The t852 isolates were also reported
among of ST22-IV MRSA isolated in Zurich, Switzerland, be-
tween 2012 and 2014 [34], pointing to their spread in Euro-
pean hospitals.
Surprisingly, the ST22-IVh-t032 isolates related to the UK
EMRSA-15/Barnim MRSA clone [10] were less common in this
study. Similarly, ST22-IV MRSA related to UK EMRSA-15/Barnim
MRSA clone was detected only in 8.9% of MRSA in a hospital in
Riyadh, Saudi Arabia [17]. Also, t032, which was the dominant
spa type of ST22-IV-MRSA in a United Arab Emirates hospital in
2003, was replaced by t005 in 2008, with none of the 2008
isolates carrying t032 [18]. Furthermore, none of ST22-IV-MRSA
reported recently in Qatar [19] and Oman [20] belonged to
t032, suggesting a displacement of t032 isolates in Kuwait and
other GCC hospitals, in contrast to its continued spread in
Europe [8,10,29], Malaysia [15] and Singapore [12]. Similar to
t032, t790 isolates, which were detected in small numbers in this
study, constituted the dominant EMRSA-15 spa type in central
Iran [35]. These studies highlight the genetic diversity of ST22-IV
subtypes in different countries and the importance of molecular
subtyping in understanding their epidemiology.© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4The UK EMRSA-15/Barnim clone has been associated with
invasive infections and has been the dominant cause of blood-
stream infections in European countries [3,8]. In contrast, the
ST22 isolates in this study were obtained mostly from skin and
soft tissue infections and colonization sites. Similarly, the majority
of ST22-IV isolates reported from Indian hospitals [33] and day
care centres in the United States [36] were from carriers,
probably reﬂecting the genetic diversity observed in this study
and the ability of the clones to survive and proliferate under
different environments which support their global spread.
All ST22-IV-MRSA isolates in this study possessed egc (seg, sei,
selm, seln, selo and selu), as has been reported in other studies
[29,37,38], implying that egc is a major virulence factor for ST22-
IV-MRSA isolates. However, the PVL-positive t852 isolates
lacked genes for staphylococcal complement inhibitor (scn), alpha
haemolysin (hla) and the A component of haemolysins gamma
(hlgA), highlighting genetic changes in the emerging variant.
The majority of the ST22-IV-MRSA isolates were resistant to
trimethoprim, erythromycin and clindamycin, as has been re-
ported in ST22-IV-MRSA isolates obtained in Ireland [39].ConclusionsThis study revealed that CC22-IV[tst1+] UK EMRSA-15/
Middle Eastern variant is the dominant EMRSA-15 variant
in Kuwait, followed by the PVL-positive, multiresistant t852
variant, with only few of the isolates related to the European
EMRSA-15/Barnim variant of spa type t032. The presence of
a mixed population of MRSA isolates poses unique problems
for infection control. The study has enriched ouriology and Infectious Diseases, NMNI, 12, 24–30
.0/).
NMNI Udo et al. EMRSA-15 in Kuwait hospitals 29understanding of the epidemiology of EMRSA-15 in Kuwait,
emphasizing the need for continuous surveillance of MRSA in
healthcare facilities to detect changes in their clonal
composition and distribution.
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